Schrödinger's First Q2 Hit: 27% Software Growth, but the Real Test Starts After Yesterday's Report

Software ACV improved, and that changes the story

Schrödinger's after-close update put the stock back on investors' radars for a solid reason: the core software demand signal looked healthier, not just the surrounding narrative. Management said software ACV rose 27% year over year to $29.6 million, with growth supported by large pharmaceutical, biotech, and materials-science customers. That matters because it suggests demand is holding up even while lab budgets are still rebuilding.

The bull case is straightforward. If the platform is growing at that pace, current earnings noise may be hiding underlying demand rather than exposing weak demand.

The bear case is about mix and timing, not product appeal. Schrödinger said hosted revenue reached 47% of software revenue, up from 31% a year ago, and that the hosted shift temporarily pressures reported revenue and software gross margin because hosted contracts are recognized ratably. So ACV can still look cleaner than booked results while that transition continues.

Q1 and Q2 both support the demand story

One quarter can be noisy. Two quarters in a row are harder to dismiss.

Schrödinger reported first-quarter ACV of $28.4 million, up 12%, with management citing usage scale-ups, new deployments, and an improving biopharmaceutical funding environment. In Q2, the company then reported software ACV rose 27% year over year to $29.6 million, with support from large pharmaceutical, biotech, and materials-science customers.

That sequence makes the demand case more credible. Strong results can be a headline cycle once. Strong results across two quarters, while the company is still moving customers toward hosted software, are harder to write off.

Bunsen and enterprise deals matter only if they drive usage

Management also said Bunsen, its agentic AI co-scientist, is now in early access and should increase platform usage, expand the user base, and speed up internal and customer drug-discovery workflows. That is a more useful launch metric than logo collection because it ties directly to adoption.

Schrödinger likewise signed a strategic agreement with Bristol Myers Squibb. The important test there is not the headline value of the partner name, but whether the relationship deepens actual workflow use inside a major sponsor.

The funding backdrop still matters. Management has tied part of this momentum to improving biotech funding, and the CEO made the same point last quarter. When budgets tighten, software is often one of the first costs trimmed. When funding improves, teams tend to expand pilots, add seats, and move from experimental use to broader deployment.

The main pushback remains valid: ACV is not booked revenue, and early-access launches can sound bigger than they are. The next few reports need to show that usage and adoption are keeping pace with the story.

The next few quarters will decide how much to trust the setup

The key question now is whether the story survives the next few scorecards.

With the company's 2026 full-year and third-quarter outlook still fresh, the near-term reports should show whether demand is translating into cleaner execution rather than just stronger messaging. That is when a compelling narrative starts to earn more credibility.

What would strengthen the case

• Reported revenue and margin behavior that improves as the hosted transition continues.
• Evidence that customer expansion is broadening beyond the largest sponsors.
• Signs that Bunsen and strategic partnerships are increasing actual product usage over time.

What would weaken it

If reported revenue and margin keep taking hits while the hosted transition drags, or if management stops linking demand to improving biotech funding and customer expansion, investors should treat recent ACV strength as less durable. A quieter-than-expected Bunsen rollout, or softer language on customer adoption, would also be warning signs.

For now, this still looks like a watch-first, size-later name. The demand signal is better than it was, but the better setup may be waiting for the next two to three quarters of confirmation.